MINNEAPOLIS, May 25, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 43rd Annual Growth Stock Conference on Thursday, June 8, 2023. The Company is scheduled to present at the conference at 9:20 am Central Time (10:20 am Eastern Time).A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com.About CVRx, Inc.CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.Investor Contact:Mark Klausner or Mike VallieICR Westwicke443-213-0501[email protected]Media Contact:Laura O’NeillFinn Partners402-499-8203[email protected]
CVRx to Present at the William Blair 43rd Annual Growth Stock Conference
Story so far
Earlier from CVRx
- CVRx Reports First Quarter 2023 Financial and Operating Results
- CVRx to Report First Quarter 2023 Financial and Operating Results and Host Conference Call on April 27th, 2023
- Totality of Evidence from BeAT-HF Study Shows CVRx’s Barostim Provides Long-term Benefits for Patients with Heart Failure
- CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call
- CVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial
Later from CVRx
- CVRx Set to Join Russell 2000 & 3000 Indexes
- CVRx to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call on July 25th, 2023
- CVRx Reports Second Quarter 2023 Financial and Operating Results
- CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference
- CVRx to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call on October 26th, 2023
Follow CVRx into a list and get an email when it puts out news.
Follow CVRx